Nonresponse and recurrence of retinopathy of prematurity after intravitreal ranibizumab treatment

Tsengelmaa Chuluunbat, R. V.Paul Chan, Nan Kai Wang, Reyin Lien, Yen Po Chen, An Ning Chao, Kuan Jen Chen, Tun Lu Chen, Yih Shiou Hwang, Chi Chun Lai, Wei Chi Wu*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

10 Scopus citations

Abstract

Background and objective: To evaluate the surgical outcome of type 1 retinopathy of prematurity (ROP) after intravitreal ranibizumab (IVR) (Lucentis; Genentech, South San Francisco, CA) treatment. patients and methods: This was a prospective case series. Premature infants with treatment-requiring ROP who received IVR injections from 2013 to 2015 were included. results: Twenty-two eyes of 12 children were included in the study. Complete resolution of ROP after a single IVR was noted in 73% of eyes. Retreatment was needed in 27% of eyes due to nonresponse to IVR (18%) or recurrence of ROP (9%). After that, all treated eyes (100%) demonstrated regressed ROP with attached retina. The median visual acuity was 0.3 Log MAR (range: 0 Log MAR to 0.8 Log MAR) with a mean follow-up of 25.2 months ± 6.8 months. conclusions: IVR is effective and well-tolerated for patients with treatment-requiring ROP. However, non response to IVR or recurrence of ROP after IVR was noted in 27% of treated eyes and required additional treatment.

Original languageEnglish
Pages (from-to)1095-1105
Number of pages11
JournalOphthalmic Surgery Lasers and Imaging Retina
Volume47
Issue number12
DOIs
StatePublished - 12 2016

Fingerprint

Dive into the research topics of 'Nonresponse and recurrence of retinopathy of prematurity after intravitreal ranibizumab treatment'. Together they form a unique fingerprint.

Cite this